Atlas Trials

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

Clinical trial NCT04405570 · COMPLETED

Trial details

NCT number
NCT04405570
Sponsor
Ridgeback Biotherapeutics, LP
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
SARS-CoV-2 Infection, COVID-19
Start date
2020-06-19
Primary completion
2021-02-21
Enrollment
204

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.